Congress Wealth Management LLC DE Invests $340,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Congress Wealth Management LLC DE purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 23,679 shares of the company’s stock, valued at approximately $340,000.

Other large investors also recently bought and sold shares of the company. Atria Wealth Solutions Inc. boosted its stake in shares of 10x Genomics by 9.6% during the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock worth $155,000 after acquiring an additional 943 shares in the last quarter. Blue Trust Inc. boosted its position in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC grew its holdings in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Signaturefd LLC increased its position in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of 10x Genomics by 57.3% during the 4th quarter. KBC Group NV now owns 5,072 shares of the company’s stock worth $73,000 after buying an additional 1,847 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on TXG shares. JPMorgan Chase & Co. decreased their price objective on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Barclays lowered their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Citigroup reduced their target price on 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $25.00 to $12.00 in a research note on Thursday, February 13th. Finally, Stifel Nicolaus reduced their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average target price of $20.21.

Insider Buying and Selling at 10x Genomics

In related news, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is owned by corporate insiders.

10x Genomics Stock Performance

TXG stock opened at $9.16 on Friday. 10x Genomics, Inc. has a one year low of $8.92 and a one year high of $37.86. The firm’s 50 day moving average price is $12.12 and its 200-day moving average price is $15.09. The firm has a market cap of $1.12 billion, a PE ratio of -6.03 and a beta of 1.93.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.